Phoqus Share Discussion Threads

[seanmiller] 19/3/2008 15:28

bounce time lol

love watching these on lvl 2 ;)

might have a cheeky few quid, ill wait to see if it goes to 12p mid.....

[crosswire] 04/3/2008 06:36

Tiddler to watch

Phoqus Pharmaceuticals rose 1p to 26p after saying that trials of Chronocort, its cortisone replacement drug, appeared to show that it controlled cortisone release in patients. It intends to apply for Phase-III clinical trials in the European Union and the United States. Nomura Code reiterated its "buy" advice.


From The TimesMarch 4, 2008

In the know

[kalingalinga] 03/12/2007 22:06

but not yet...

[kalingalinga] 03/8/2007 21:12

think i may have a bit of this..

[singsing] 03/7/2007 10:26

Yes its that time im afraid. Get in now.

[wiganer] 11/12/2005 22:11

weren't they a Dutch rock band from the 70s?

[cortez] 11/12/2005 21:37

No reply to my e-mail. Current royalties seem small at between 3 and 7%, looks very much like a slow burner to me.

[chay01] 07/12/2005 10:07

Enquiries:

Phoqus Group plc
Tel: [phone]
Andy Jones, Chief Executive Officer
Peter Johnson, Chief Financial Officer

Financial Dynamics
Tel: [phone]
Sarah MacLeod / John Gilbert

Notes to editors

About Phoqus

Phoqus is a drug delivery company using proprietary electrostatic powder coating technology, LeQtracoat®, to provide an extensive range of innovative systems targeting the oral drug delivery market. Phoqus has five collaboration agreements, three of which are with leading pharmaceutical companies. Phoqus is the only company using electrostatic powder coating technology for pharmaceutical applications and has over 120 granted patents.

The Company's products target the established and growing oral drug delivery sector, which is valued at over $31 billion, and address the major oral sectors including modified release, fast dissolve, low dose and combination drugs. Drug delivery technologies are applied to pharmaceuticals to provide benefits such as controlling the release of a drug into the body, enhancing patient compliance and improving the performance and efficacy of an existing drug. In turn, these benefits enable pharmaceutical companies to extend the life cycles of their products, strengthen their patent protection and thereby enhance the value of their marketed products and development pipelines.

In addition, the Company has developed its coating technology to create novel images on drug tablets as a means of brand enhancement and protection against counterfeiting.

Phoqus has also been successful in developing additional applications for the LeQtracoat® technology in pharmaceutical capsules, medical devices and detergent tablets, and is in discussions regarding potential collaborations with several leading companies in these areas.

To assist the delivery of its strategy, Phoqus has entered into a strategic partnership with Cardinal Health, the world's largest supplier of services to the healthcare industry, to provide commercial scale GMP manufacturing to collaboration partners. Cardinal Health also co-markets Phoqus' drug delivery and image enhancement systems in all major markets.

Phoqus, based in Kent, was established in 1998 as a spin-out from Colorcon, a division of Berwind Pharmaceutical Services Inc.

The Company was admitted to trading on AIM in November 2005 raising £10m and is listed on AIM under the symbol "PQS".

Further background on the Company can be found at www.phoqus.com.

About Biofusion

Biofusion was established in 2002 to commercialise university-generated IP. In February 2005 Biofusion listed on Aim and raised £8.2m for the commercialisation of IP owned by the University of Sheffield in the area of medical life sciences. It has agreed a ten-year exclusive arrangement with the University which also gives Biofusion shareholdings in an existing portfolio of eight spin-out companies. The University of Sheffield is a world class life sciences research centre, spending £30m in 2002/3 on research in medical life sciences. This spending level is expected to grow year on year giving an estimated £0.5bn of research funding over the next ten years. The University, which celebrates its centenary this year, can count five Nobel Prize winners among its alumni and researchers, and data from the latest UK Government's Research Assessment Exercise 2001 ("RAE 2001") showed it ranked fifth in the UK for the quality of its life sciences research. Biofusion is listed on AIM under the symbol "BFN".

Further background on the Company can be found at www.biofusion.com.

About Diurnal

Diurnal is a spin-out from the University of Sheffield, and is a Biofusion plc portfolio company in which Biofusion now has a fully diluted shareholding of 60%.

Biofusion plc was established in 2002 to commercialise university-generated IP. In February 2005 Biofusion plc listed on AIM and raised £8.2m for the commercialisation of IP owned by the University of Sheffield in the area of medical life sciences. It has agreed a ten-year exclusive arrangement with the University which also gives Biofusion shareholdings in an existing portfolio of eight spin-out companies.

Founded in 2004, Diurnal seeks to develop means for the controlled and sustained release of steroids and intends its first product to be based on the delivery of hydrocortisone, in a manner which mimics the circadian rhythm. This marked rhythm, with high levels in the morning and low levels at night, is lost in patients with adrenal insufficiency. The Diurnal management believe that their product will offer a potential much needed improvement in steroid treatment for patients with congenital adrenal hyperplasia, a form of adrenal insufficiency.

Diurnal also intends to explore additional opportunities for new indications in areas in which cortisol levels may be implicated in other diseases (such as inflammatory conditions).

[currypasty] 07/12/2005 08:37

RNS Number:2617V
Phoqus Group plc
07 December 2005



Phoqus announces start of Phase I clinical study on Chronocort


West Malling, UK, 7 December 2005: Phoqus Group plc ("Phoqus" or the "Company")
(AIM:PQS), the newly AIM-listed oral drug delivery and development company,
announces that its in-house development programme in collaboration with Diurnal
Limited ("Diurnal"), a subsidiary of Biofusion plc, has begun its Phase I
clinical trials programme on Chronocort - the first Circadian endocrine
treatment for adrenal insufficiency.


Phoqus has a collaboration with Diurnal to develop Chronocort, a once-daily
modified release hydrocortisone tablet for the treatment of adrenal
insufficiency, a condition which causes Addison's disease, hypopituitarism and
congenital adrenal hyperplasia. Current steroid therapies for these conditions
do not mimic the natural circadian rhythm of the native steroid hormone,
creating an unmet need in the worldwide market valued at in excess of #75
million per year. Phoqus believes that a sustained-release tablet using its
technologies would address this need effectively and provide a much needed
treatment.


The initial Phase I trial, which will involve healthy volunteers dosed with the
modified release hydrocortisone tablet formulation, is expected to be completed
in early 2006. The objective is to evaluate the correlation between in-vitro
hydrocortisone releases with the in-vivo blood levels observed following oral
administration.


Under the terms of the Diurnal agreement, Phoqus is supplying the tablets for
the drug, which has already obtained orphan medicinal product designation in the
EU.


Andy Jones, Chief Executive Officer of Phoqus, commented:


"We are delighted that Chronocort has entered Phase I. Our technology allows
the modified release of the drug into the patient which we believe is crucial
for effective treatment, and should greatly benefit patients with simplified
dosing and reduced side effects. "


David Baynes, Chief Executive Officer of Biofusion, said:


"We are pleased to see Chronocort entering Phase I clinical trials as planned.
We value Diurrnal's partnership with Phoqus, and look forward to progressing
this product to the market with them."

[cortez] 05/12/2005 22:06

Looks solid, good management, and the relationship with Cardinal Health is very encouraging. I see GlaxoSmithKline get a mention too. Burning around £7m a year though so an RI further out looks likely. On the other hand commercialisation alleged to be near and with CH co-marketing....

Hard to say, I'd guess at nothing spectacular, more of a tuck away if you like it enough. Interesting that the cap is significantly less than BPRG though.

No on-line accounts so I've requested a copy.

[currypasty] 03/11/2005 08:41

not much to say yet...like the name though, pronounced 'fuc'-'us'